Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

PRMT5 inhibition shows in vitro efficacy against H3K27M-altered diffuse midline glioma, but does not extend survival in vivo.

Scientific reports - 3 Jan 2024

Brown Elizabeth J, Balaguer-Lluna Leire, Cribbs Adam P, Philpott Martin, Campo Leticia, Browne Molly, Wong Jong Fu, Oppermann Udo, Carcaboso Ángel M, Bullock Alex N, Farnie Gillian

Abstract excerpt

H3K27-altered Diffuse Midline Glioma (DMG) is a universally fatal paediatric brainstem tumour. The prevalent driver mutation H3K27M creates a unique epigenetic landscape that may also establish therapeutic vulnerabilities to epigenetic inhibitors. However, while HDAC, EZH2 and BET inhibitors have proven somewhat effective in pre-clinical models, none have translated into clinical benefit due to either poor...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Blood-Brain Barrier
Share to Brain Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Brain Stem Neoplasms

Share to Cell Survival

Share to Combined Modality Therapy

Share to Glioma

Share to Protein-Arginine N-Methyltransferases

Source

Open in PubMed Open full text

Identifiers

PMID: 38172189
DOI: 10.1038/s41598-023-48652-x
PMCID: PMC10764357

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PRMT5 inhibition shows in vitro efficacy against H3K27M-altered diffuse midline glioma, but does not extend survival in vivo.PMID 38172189Read ↗

H3K27-Altered Diffuse Midline Glioma of the Brainstem: From Molecular Mechanisms to Targeted Interventions.Semantic proximity Read ↗

Epigenetic-Targeted Treatments for H3K27M-Mutant Midline Gliomas.Semantic proximity Read ↗

Therapeutic Targets in Diffuse Midline Gliomas—An Emerging LandscapeSemantic proximity Read ↗

Bench-to-bedside investigations of H3 K27-altered diffuse midline glioma: drug targets and potential pharmacotherapies.Semantic proximity Read ↗

Therapeutic HDAC inhibition in hypermutant diffuse intrinsic pontine gliomaSemantic proximity Read ↗

Panobinostat in adults with H3 K27M-mutant diffuse midline glioma: a single-center experience.Semantic proximity Read ↗

Emerging Advances in Combinatorial Treatments of Epigenetically Altered Pediatric High-Grade H3K27M GliomasSemantic proximity Read ↗

STAT3 is a biologically relevant therapeutic target in H3K27M-mutant diffuse midline glioma.Semantic proximity Read ↗

Diffuse midline glioma treated with epigenetic agent-based immunotherapySemantic proximity Read ↗

Pediatric diffuse midline glioma: Understanding the mechanisms and assessing the next generation of personalized therapeuticsSemantic proximity Read ↗

Optimal therapeutic targeting by HDAC inhibition in biopsy-derived treatment-naïve diffuse midline glioma models.Semantic proximity Read ↗

Pharmaco-proteogenomic profiling of pediatric diffuse midline glioma to inform future treatment strategiesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.